IndustryCompany release

CytoSorbents reaches operating cash flow breakeven in Q3 as revenue edges up 3%

🇺🇸 Cytosorbents Corp (CTSO) · Thu 12 Nov 2026

The blood purification company reports $9.7M quarterly revenue and a narrower operating loss, while it pursues FDA marketing authorization for DrugSorb-ATR and tries to rebuild German sales.

CytoSorbents reported third-quarter 2026 results on 12 November. Revenue rose 3% to $9.7M, and gross margin was 75%. The operating loss narrowed by 59% to $1.2M.

The company said it reached operating cash flow breakeven in the quarter, excluding restructuring payments. It ended the period with about $5.7M in cash.

CytoSorbents also updated investors on what it calls its four value drivers. These include seeking FDA marketing authorization for DrugSorb-ATR in the US, and rebuilding sales in Germany, where revenue fell 20%.

For context, medical devices in the US generally reach the market through FDA clearance, De Novo classification or premarket approval, depending on risk and on whether a suitable predicate exists. The summary available does not specify which route CytoSorbents is pursuing for DrugSorb-ATR.

What it means for your team

  • A US marketing authorization for DrugSorb-ATR remains a stated company priority, so regulatory teams should watch for formal FDA milestones, which the update does not detail.
  • The 20% drop in German sales shows how much a single large European market can affect a device maker's results; market-access teams may want to track how the company rebuilds there.
  • Breakeven is reported excluding restructuring payments, and cash of about $5.7M is modest, so the company's financial position is worth monitoring.

Company's press release (SEC filing): Cytosorbents Corp ↗

Article written by VigiEye from the official source (Cytosorbents Corp). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →